Divis Laboratories Share Price
Sector: Biotechnology & Drugs
6106.50 +97.30 (1.62%)
- 1D
- 5D
- 1M
- 3M
- 6M
- 1Y
- 5Y
- MAX
Price Range
Today’s Low
6012
Today’s High
6123.55
52 Week Low
3674.20
52 Week High
6448.75
6103.00 +90.50 (1.51%)
- 1D
- 5D
- 1M
- 3M
- 6M
- 1Y
- 5Y
- MAX
Price Range
Today’s Low
6012
Today’s High
6125
52 Week Low
3675
52 Week High
6308.50
Key Metrics
- Market Cap (In Cr) 162108.39
- Beta 0.68
- Div. Yield (%) 0.5
- P/B 11.76
- TTM P/E 78.35
- Peg Ratio -11.16
- Sector P/E 0
- Open Price 6021.8
- Prev Close 6009.2
Divis Laboratories Analysis
Price Analysis
-
1 Week6.6%
-
3 Months4.34%
-
6 Month4.01%
-
YTD-1.42%
-
1 Year56.42%
Risk Meter
- 31% Low risk
- 31% Moderate risk
- 31% Balanced Risk
- 31% High risk
- 31% Extreme risk
Recos
- Strong Sell
- Sell
- Hold
- Buy
- Strong Buy
Analysts' Views
- Ratings
- Current
- 1 W Ago
- 1 M Ago
- 3 M Ago
- Strong Buy
- 3
- 3
- 3
- 3
- Buy
- 4
- 4
- 4
- 4
- Hold
- 5
- 5
- 5
- 5
- Sell
- 5
- 5
- 5
- 5
- Strong Sell
- 5
- 5
- 5
- 6
- Total
- 22
- 22
- 22
- 23
Divis Laboratories News
Top events on Nov 9: Asian Paints, Aurobindo Pharma Q2 results, Uttarakhand UCC
2 min read . 09 Nov 2024Nifty Sept rejig: BEL, Trent to enter NSE index on Sept 27; Divi's Lab excluded
2 min read . 26 Sep 2024Divis Laboratories Financials
- INCOME
- BALANCE SHEET
- Cashflow
- Period
- 2024
- Total Revenue
- 7845
- Selling/ General/ Admin Expenses Total
- 1811
- Depreciation/ Amortization
- 378
- Total Operating Expense
- 6014
- Operating Income
- 1831
- Net Income Before Taxes
- 2163
- Net Income
- 1600
- Diluted Normalized EPS
- 60.38
- Period
- 2024
- Total Assets
- 15470
- Total Liabilities
- 1899
- Total Equity
- 13571
- Tangible Book Valueper Share Common Eq
- 511.06
- Period
- 2024
- Cashfrom Operating Activities
- 1261
- Cashfrom Investing Activities
- -269
- Cashfrom Financing Activities
- -799
- Net Changein Cash
- 193
- Period
- 2023
- Total Revenue
- 7767.51
- Selling/ General/ Admin Expenses Total
- 1654.4
- Depreciation/ Amortization
- 343.18
- Total Operating Expense
- 5741.74
- Operating Income
- 2025.77
- Net Income Before Taxes
- 2368.63
- Net Income
- 1823.38
- Diluted Normalized EPS
- 68.72
- Period
- 2023
- Total Assets
- 14438.77
- Total Liabilities
- 1671.68
- Total Equity
- 12767.09
- Tangible Book Valueper Share Common Eq
- 480.73
- Period
- 2023
- Cashfrom Operating Activities
- 2459.73
- Cashfrom Investing Activities
- -2707.62
- Cashfrom Financing Activities
- -797.17
- Net Changein Cash
- -1045.06
- Period
- 2022
- Total Revenue
- 8959.83
- Selling/ General/ Admin Expenses Total
- 1541.48
- Depreciation/ Amortization
- 311.51
- Total Operating Expense
- 5387.35
- Operating Income
- 3572.48
- Net Income Before Taxes
- 3683.5
- Net Income
- 2960.45
- Diluted Normalized EPS
- 111.58
- Period
- 2022
- Total Assets
- 13374.71
- Total Liabilities
- 1646.53
- Total Equity
- 11728.18
- Tangible Book Valueper Share Common Eq
- 441.51
- Period
- 2022
- Cashfrom Operating Activities
- 1911.8
- Cashfrom Investing Activities
- -2194.92
- Cashfrom Financing Activities
- -532.44
- Net Changein Cash
- -815.56
- Period
- 2021
- Total Revenue
- 6969.4
- Selling/ General/ Admin Expenses Total
- 1306
- Depreciation/ Amortization
- 255.59
- Total Operating Expense
- 4354.71
- Operating Income
- 2614.69
- Net Income Before Taxes
- 2666.04
- Net Income
- 1984.29
- Diluted Normalized EPS
- 74.91
- Period
- 2021
- Total Assets
- 10774.07
- Total Liabilities
- 1479.46
- Total Equity
- 9294.61
- Tangible Book Valueper Share Common Eq
- 349.93
- Period
- 2021
- Cashfrom Operating Activities
- 1946.93
- Cashfrom Investing Activities
- 75.13
- Cashfrom Financing Activities
- -34.89
- Net Changein Cash
- 1987.17
- Period
- 2020
- Total Revenue
- 5394.42
- Selling/ General/ Admin Expenses Total
- 1061.8
- Depreciation/ Amortization
- 186.24
- Total Operating Expense
- 3754.2
- Operating Income
- 1640.22
- Net Income Before Taxes
- 1819.46
- Net Income
- 1376.54
- Diluted Normalized EPS
- 51.95
- Period
- 2020
- Total Assets
- 8535.7
- Total Liabilities
- 1225.78
- Total Equity
- 7309.92
- Tangible Book Valueper Share Common Eq
- 275.22
- Period
- 2020
- Cashfrom Operating Activities
- 1215.94
- Cashfrom Investing Activities
- -83.47
- Cashfrom Financing Activities
- -1091.42
- Net Changein Cash
- 41.05
- Period
- 2019
- Total Revenue
- 4946.26
- Selling/ General/ Admin Expenses Total
- 881.55
- Depreciation/ Amortization
- 168.9
- Total Operating Expense
- 3240.75
- Operating Income
- 1705.51
- Net Income Before Taxes
- 1855.07
- Net Income
- 1352.74
- Diluted Normalized EPS
- 50.99
- Period
- 2019
- Total Assets
- 8038.25
- Total Liabilities
- 1081.1
- Total Equity
- 6957.15
- Tangible Book Valueper Share Common Eq
- 261.92
- Period
- 2019
- Cashfrom Operating Activities
- 954.3
- Cashfrom Investing Activities
- -685.4
- Cashfrom Financing Activities
- -245.94
- Net Changein Cash
- 22.96
- Period
- 2018
- Total Revenue
- 3912.78
- Selling/ General/ Admin Expenses Total
- 757.07
- Depreciation/ Amortization
- 142.49
- Total Operating Expense
- 2787.3
- Operating Income
- 1125.48
- Net Income Before Taxes
- 1231.33
- Net Income
- 877.01
- Diluted Normalized EPS
- 33.2
- Period
- 2018
- Total Assets
- 6785.85
- Total Liabilities
- 861.05
- Total Equity
- 5924.8
- Tangible Book Valueper Share Common Eq
- 222.94
- Period
- 2018
- Cashfrom Operating Activities
- 775.86
- Cashfrom Investing Activities
- -478.3
- Cashfrom Financing Activities
- -314.16
- Net Changein Cash
- -16.6
- Period
- 2024-12-31
- Total Revenue
- 2319
- Selling/ General/ Admin Expenses Total
- 297
- Depreciation/ Amortization
- 99
- Other Operating Expenses Total
- 357
- Total Operating Expense
- 1675
- Operating Income
- 644
- Net Income Before Taxes
- 726
- Net Income
- 589
- Diluted Normalized EPS
- 22.2
- Period
- 2024-12-31
- Period
- 2024-12-31
- Period
- 2024-09-30
- Total Revenue
- 2338
- Selling/ General/ Admin Expenses Total
- 304
- Depreciation/ Amortization
- 99
- Other Operating Expenses Total
- 349
- Total Operating Expense
- 1721
- Operating Income
- 617
- Net Income Before Taxes
- 722
- Net Income
- 510
- Diluted Normalized EPS
- 19.2
- Period
- 2024-09-30
- Total Assets
- 15586
- Total Liabilities
- 1869
- Total Equity
- 13717
- Tangible Book Valueper Share Common Eq
- 516.56
- Period
- 2024-09-30
- Cashfrom Operating Activities
- 926
- Cashfrom Investing Activities
- -459
- Cashfrom Financing Activities
- -792
- Net Changein Cash
- -325
- Period
- 2024-06-30
- Total Revenue
- 2118
- Selling/ General/ Admin Expenses Total
- 292
- Depreciation/ Amortization
- 97
- Other Operating Expenses Total
- 351
- Total Operating Expense
- 1593
- Operating Income
- 525
- Net Income Before Taxes
- 604
- Net Income
- 430
- Diluted Normalized EPS
- 16.2
- Period
- 2024-06-30
- Period
- 2024-06-30
- Period
- 2024-03-31
- Total Revenue
- 2303
- Selling/ General/ Admin Expenses Total
- 297
- Depreciation/ Amortization
- 95
- Other Operating Expenses Total
- 371
- Total Operating Expense
- 1665
- Operating Income
- 638
- Net Income Before Taxes
- 713
- Net Income
- 538
- Diluted Normalized EPS
- 20.24
- Period
- 2024-03-31
- Total Assets
- 15470
- Total Liabilities
- 1899
- Total Equity
- 13571
- Tangible Book Valueper Share Common Eq
- 511.06
- Period
- 2024-03-31
- Cashfrom Operating Activities
- 1261
- Cashfrom Investing Activities
- -269
- Cashfrom Financing Activities
- -799
- Net Changein Cash
- 193
- Period
- 2023-12-31
- Total Revenue
- 1855
- Selling/ General/ Admin Expenses Total
- 268
- Depreciation/ Amortization
- 95
- Other Operating Expenses Total
- 369
- Total Operating Expense
- 1461
- Operating Income
- 394
- Net Income Before Taxes
- 489
- Net Income
- 358
- Diluted Normalized EPS
- 13.5
- Period
- 2023-12-31
- Period
- 2023-12-31
- Period
- 2023-09-30
- Total Revenue
- 1909
- Selling/ General/ Admin Expenses Total
- 266
- Depreciation/ Amortization
- 95
- Other Operating Expenses Total
- 354
- Total Operating Expense
- 1525
- Operating Income
- 384
- Net Income Before Taxes
- 469
- Net Income
- 348
- Diluted Normalized EPS
- 13.11
- Period
- 2023-09-30
- Total Assets
- 14283
- Total Liabilities
- 1606
- Total Equity
- 12677
- Tangible Book Valueper Share Common Eq
- 477.42
- Period
- 2023-09-30
- Cashfrom Operating Activities
- 539
- Cashfrom Investing Activities
- 122
- Cashfrom Financing Activities
- -798
- Net Changein Cash
- -137
- Period
- 2023-06-30
- Total Revenue
- 1778
- Selling/ General/ Admin Expenses Total
- 263
- Depreciation/ Amortization
- 93
- Other Operating Expenses Total
- 323
- Total Operating Expense
- 1367
- Operating Income
- 411
- Net Income Before Taxes
- 492
- Net Income
- 356
- Diluted Normalized EPS
- 13.41
- Period
- 2023-06-30
- Period
- 2023-06-30
- Period
- 2023-03-31
- Total Revenue
- 1950.77
- Selling/ General/ Admin Expenses Total
- 257.64
- Depreciation/ Amortization
- 87.02
- Other Operating Expenses Total
- 373.75
- Total Operating Expense
- 1545.99
- Operating Income
- 404.78
- Net Income Before Taxes
- 466.48
- Net Income
- 320.97
- Diluted Normalized EPS
- 12.09
- Period
- 2023-03-31
- Total Assets
- 14438.77
- Total Liabilities
- 1671.68
- Total Equity
- 12767.09
- Tangible Book Valueper Share Common Eq
- 480.73
- Period
- 2023-03-31
- Cashfrom Operating Activities
- 2459.73
- Cashfrom Investing Activities
- -2707.62
- Cashfrom Financing Activities
- -797.17
- Net Changein Cash
- -1045.06
- Period
- 2022-12-31
- Total Revenue
- 1707.68
- Selling/ General/ Admin Expenses Total
- 238.88
- Depreciation/ Amortization
- 86.77
- Other Operating Expenses Total
- 320.97
- Total Operating Expense
- 1386.17
- Operating Income
- 321.51
- Net Income Before Taxes
- 435.63
- Net Income
- 306.8
- Diluted Normalized EPS
- 11.56
- Period
- 2022-12-31
- Period
- 2022-12-31
Forecast
Income Sheet (In Cr)
Net Income Vs Revenue
Returns Metrics (In Cr)
ROA Vs ROE
Forecast
Balance Sheet
Asset vs Liability
Forecast
Cash Flow
Operating vs Investing
Divis Laboratories Technical
Moving Average
SMA
- 5 Day5989.36
- 10 Day5805.15
- 20 Day5710.24
- 50 Day5751.32
- 100 Day5839.15
- 300 Day5549.03
Divis Laboratories Peers
- Price
- Ratio
- Name
- Latest Price
- Change
- % Change
- 52W High
- 52W Low
- Mkt. Cap
- Sun Pharmaceutical Industries
- 1839.45
- 52.6
- 2.94
- 1960.2
- 1376.75
- 441334.9
- Divis Laboratories
- 6106.5
- 97.3
- 1.62
- 6448.75
- 3674.2
- 162108.39
- Cipla
- 1554
- 28.5
- 1.87
- 1702
- 1310.05
- 125841.92
- Torrent Pharmaceuticals
- 3330.9
- 94.95
- 2.93
- 3589.95
- 2513.05
- 112586.82
- Dr Reddys Laboratories
- 1198
- 24.45
- 2.08
- 1420.2
- 1025.9
- 100172.21
- Name
- P/E (X)
- P/B (X)
- ROE %
- OPM
- Sun Pharmaceutical Industries
- 42.83
- 6.74
- 11.27
- 14.23
- Divis Laboratories
- 99.57
- 11.76
- 18.97
- 26.38
- Cipla
- 28.38
- 4.61
- 13.5
- 12.66
- Torrent Pharmaceuticals
- 68.37
- 15.99
- 20.64
- 13.18
- Dr Reddys Laboratories
- 17.78
- 3.46
- 16.73
- 14.63
Divis Laboratories Shareholding
Shareholding Pattern
Shareholding Trend
Shareholding(%) v/s Date
Corporate Actions
- Board Meeting
- AGM
- Dividends
- Bonus
- Split
- Rights
- Meeting Date
- Purpose
- 03-Feb-25
- Quarterly Results
- 09-Nov-24
- Quarterly Results
- 03-Aug-24
- Quarterly Results
- 25-May-24
- Audited Results & Dividend
- 10-Feb-24
- Quarterly Results
- 06-Nov-23
- Quarterly Results
- 14-Aug-23
- Quarterly Results
- 20-May-23
- Audited Results & Final Dividend
- 03-Feb-23
- Quarterly Results
- 07-Nov-22
- Quarterly Results
- Meeting Date
- Announced on
- Purpose
- 08-Mar-25
- 04-Feb-25
- POM
- 12-Aug-24
- 15-Jul-24
- AGM
- 06-Apr-24
- 04-Mar-24
- POM
- 28-Aug-23
- 20-May-23
- AGM
- 22-Aug-22
- 04-Jul-22
- AGM
- 28-Mar-22
- 24-Feb-22
- POM
- 30-Aug-21
- 02-Aug-21
- AGM
- Announced on
- Record Date
- Ex-Dividend
- Dividend Value
- 27-May-24
- 02-Aug-24
- 02-Aug-24
- 30
- 22-May-23
- 11-Aug-23
- 11-Aug-23
- 30
- 23-May-22
- 12-Aug-22
- 11-Aug-22
- 30
- 31-May-21
- -
- 17-Aug-21
- 20


